FGF2 and neoplasm: It was found the addition of a specific 5-HT2B receptor antagonist in the tumour cell-containing compartment inhibited the proliferation of KRJ-I cells and significantly reduced 5-HT release, while also reducing the synthesis of transforming growth factor beta-1 (TGF-β1), connective tissue growth factor and fibroblast growth factor 2 (FGF2) (Svejda et al. 2010).